Trial intelligence / Profile preview

Allopurinol for cerebral and cardiac protection in neonates with critical congenital heart disease undergoing bypass surgery

2017-004596-31Phase 3Active

Sponsor
University Medical Center Utrecht
Start
Nov 2018
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in Cardiovascular Malformation (CVM) and traumatic brain injury (TBI) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Primary composite outcome. Started Nov 2018; status: active.

02

Drugs

allopurinol sodium
03

Conditions

Cardiovascular Malformation (CVM)traumatic brain injury (TBI)

Beyond the preview

Go deeper on 2017-004596-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-004596-31.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call